Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Neuphoria Therapeutics (NEUP) EBITDA Margin (2024 - 2025)

Historic EBITDA Margin for Neuphoria Therapeutics (NEUP) over the last 2 years, with Q2 2025 value amounting to 58915.04%.

  • Neuphoria Therapeutics' EBITDA Margin changed N/A to 58915.04% in Q2 2025 from the same period last year, while for Dec 2025 it was 27.84%, marking a year-over-year change of. This contributed to the annual value of 1.29% for FY2025, which is N/A changed from last year.
  • As of Q2 2025, Neuphoria Therapeutics' EBITDA Margin stood at 58915.04%.
  • In the past 5 years, Neuphoria Therapeutics' EBITDA Margin registered a high of 58915.04% during Q2 2025, and its lowest value of 73.78% during Q1 2025.